确成股份：2025年前三季度净利润约3.97亿元

Group 1 - The company reported a revenue of approximately 1.653 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 1.16% [1] - The net profit attributable to shareholders of the listed company was about 397 million yuan, reflecting a year-on-year growth of 4.78% [1] - The basic earnings per share reached 0.97 yuan, which is a year-on-year increase of 6.59% [1] Group 2 - The Chinese innovative drug sector has generated overseas licensing sales of 80 billion USD this year [1] - There is a notable contrast in the biopharmaceutical secondary market's activity compared to the cooling fundraising environment in the primary market [1]